H.B. Fuller Company (FUL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Apr, 2026Opening remarks and agenda
Meeting commenced virtually at 10 A.M. on April 16, 2026, with shareholders, board members, and auditors present.
Agenda included election of directors, ratification of auditors, and advisory vote on executive compensation.
Board and executive committee updates
Three directors, Daniel L. Florness, Celine C. Martin, and Teresa J. Rasmussen, were nominated for re-election to three-year terms.
All nominated directors were currently serving and recommended by the board.
Shareholder proposals
Three proposals were presented: election of directors, ratification of Ernst & Young as auditors, and an advisory vote on executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from H.B. Fuller Company
- Acquisition accelerates medical growth, expands TAM to ~$95B, and targets $55M in synergies.FUL
Acquisition presentation - Q3 net revenue up 5.2%, record 19.9% EBITDA margin, and raised 2026 guidance.FULQ3 2026
- Q2 2026 saw strong revenue, margin, and EPS growth, with a major medical acquisition announced.FULQ2 2026
- Adjusted EBITDA and EPS rose with margin expansion despite a 6.6% organic revenue decline.FULQ1 2026
- Proxy covers director elections, auditor ratification, pay, strong results, and ESG focus.FULProxy Filing
- Votes will be cast for director elections, auditor ratification, and executive pay approval.FULProxy Filing
- Adjusted EBITDA and EPS grew 5% year-over-year, with margin gains and raised full-year guidance.FULQ2 2025
- Q3 2024 saw 6% EBITDA and 7% EPS growth, led by strong Construction Adhesives results.FULQ3 2024
- Adjusted EPS up 20% and EBITDA up 10% year-over-year, with 2024 guidance raised.FULQ2 2024